Aripiprazole long-acting injection (LAI) is approved for the treatment of schizophrenia in adults. Recently, Europe and Canada approved the use of the two-injection start regimen: two separate injections of 400-mg long-acting aripiprazole along with a single 20-mg dose of oral aripiprazole. Aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13- to 17-year-old adolescents with schizophrenia by the EMA. However, the LAI formulation still remains off-label in adolescents.
Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia / Salvi, Virginio; Appignanesi, Cristina; Marpepa, Brodinela; Orsolini, Laura; Volpe, Umberto. - In: NEUROPSYCHOPHARMACOLOGY REPORTS. - ISSN 2574-173X. - 42:2(2022), pp. 241-244. [10.1002/npr2.12240]
Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia
Salvi, Virginio;Appignanesi, Cristina;Marpepa, Brodinela;Orsolini, Laura;Volpe, Umberto
2022-01-01
Abstract
Aripiprazole long-acting injection (LAI) is approved for the treatment of schizophrenia in adults. Recently, Europe and Canada approved the use of the two-injection start regimen: two separate injections of 400-mg long-acting aripiprazole along with a single 20-mg dose of oral aripiprazole. Aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13- to 17-year-old adolescents with schizophrenia by the EMA. However, the LAI formulation still remains off-label in adolescents.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
